http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Aijun Chen (검색결과 9 건)
- 무료
- 기관 내 무료
- 유료
-
Interval Estimation for Discrete-time Descriptor System Based on Zonotopic Kalman Filter
Aijun Chen,Mingjian Sun,Yi Shen,Yuan Liu 제어·로봇·시스템학회 2022 International Journal of Control, Automation, and Vol.20 No.6
This paper investigates the problem of interval estimation for discrete-time linear descriptor systems subject to unknown-but-bounded uncertainties. Based on prediction-correction mechanism, we proposed a twostep interval estimator to over-estimate the bounds of the system states. To reduce the conservatism, a novel parameterization-based approach is presented. Besides, by using a Frobenius norm-based minimization approach, optimal correction is calculated. Compared to the volume criterion, the computational efficiency is greatly enhanced. Finally, two numerical examples are presented to illustrate the efficiency and potential application of the proposed approach.
-
Aijun Li,Lin Chen,Yanchun Zhou 한국세라믹학회 2012 한국세라믹학회지 Vol.49 No.4
Based on the structure feature of a tree, a cylindrical Ti2AlC/graphite layered composite has been fabricated through heat treating a graphite column and six close-matched thin wall Ti2AlC cylinders bonded with the Ti2AlC powders at 1300oC and low oxygen partial pressure. SEM examination reveals that the bond interlayers between cylinders or that between cylinder and column are not fully dense without any crack formation. During the compressive test, the strain of the Ti2AlC/graphite layered composite is about twice higher than that of the monolithic Ti2AlC ceramic, and the compressive strength of the layered composite is 348 MPa. The layered composite show the noncatastrophic fracture behaviors due to the debonding and shelling off of the layers, which are different from the monolithic Ti2AlC ceramic. The mechanism of the improved deformation capacity and noncatastrophic failure modes are attributed to the presence of the central soft graphite column and cracks deflection by the bond interlayers.
-
Li, Aijun,Chen, Lin,Zhou, Yanchun The Korean Ceramic Society 2012 한국세라믹학회지 Vol.49 No.4
Based on the structure feature of a tree, a cylindrical $Ti_2AlC$/graphite layered composite has been fabricated through heat treating a graphite column and six close-matched thin wall $Ti_2AlC$ cylinders bonded with the $Ti_2AlC$ powders at $1300^{\circ}C$ and low oxygen partial pressure. SEM examination reveals that the bond interlayers between cylinders or that between cylinder and column are not fully dense without any crack formation. During the compressive test, the strain of the $Ti_2AlC$/graphite layered composite is about twice higher than that of the monolithic $Ti_2AlC$ ceramic, and the compressive strength of the layered composite is 348 MPa. The layered composite show the noncatastrophic fracture behaviors due to the debonding and shelling off of the layers, which are different from the monolithic $Ti_2AlC$ ceramic. The mechanism of the improved deformation capacity and noncatastrophic failure modes are attributed to the presence of the central soft graphite column and cracks deflection by the bond interlayers.
-
Modalities in managing postherpetic neuralgia
( Meera Shrestha ),( Aijun Chen ) 대한통증학회 2018 The Korean Journal of Pain Vol.31 No.4
Postherpetic neuralgia (PHN) is the most troublesome side effect of Herpes Zoster (HZ), which mainly affects the elderly and immunocompromised populations. Despite the current advancement of treatments, PHN persists in many individuals influencing their daily activities and reducing their quality of life. Anticonvulsants, antidepressants, topical therapies including lidocaine and capsaicin, and opioids, are the most widely used therapies for the treatment of PHN. These medications come with their adverse effects, so they should be used carefully with the elderly or with patients with significant comorbidities. Other measures like botulinum toxin, nerve blocks, spinal cord stimulation, and radiofrequency have also contributed significantly to the management of PHN. However, the efficacy, safety, and tolerability of these invasive methods need to be carefully monitored when administering them. Early diagnosis and early initiation of treatment can reduce the burden associated with PHN. The zoster vaccine has effectively reduced the incidence of HZ and PHN. In this article, we discuss the treatment options available for the management of PHN, mainly focusing on the efficacy and safety of different therapeutic modalities. (Korean J Pain 2018; 31: 235-43)
-
-
Cunhua Ma,Bin Dai,Ping Liu,Na Zhou,Aijun Shi,Lili Ban,Hongwei Chen 한국공업화학회 2014 Journal of Industrial and Engineering Chemistry Vol.20 No.5
The dielectric barrier discharge (DBD) is often used to prepare ozone. In this study, a novel room temperature oxidative desulfurization method involving ozone oxidation produced in the DBD reactor combined with ionic liquid (IL) [BMIM]CH3COO ([BMIM]Ac) extraction was developed. The method was suitable for the deep removal of sulfur (S)-containing compounds from model fuel. By this desulfurization technology, 4,6-dimethyldibenzothiophene (4,6-DMDBT), dibenzothiophene (DBT), benzothiophene (BT) and thiophene (TS) were efficiently removed. Normally, the removal of TS and BT from fuel is highly difficult. However, using the proposed method of this study without any catalyst, the removal rate of TS and BT reached 99.9%. When TiO2/MCM-41 was used as a catalyst, the S-removal of DBT and 4,6-DMDBT increased to 98.6 and 95.2%, respectively. The sulfur removal activity of the four sulfur compounds decreased in the order of TS > BT >> DBT > 4,6-DMDBT. 2013 The Korean Society of Industrial and Engineering Chemistry. Published by Elsevier B.V. All rights reserved.
-
Weipeng Liu,Xin Zhou,Yuanqiang Li,Hong Jiang,Aijun Chen 한국유방암학회 2021 Journal of breast cancer Vol.24 No.3
Purpose: Non-coding RNA activated by DNA damage (NORAD) has been reported to be a cancer-related long non-coding RNA (lncRNA) implicated in the progression of several cancers; however, its role in breast cancer (BC) has not yet been clarified. Methods: Quantitative real-time polymerase chain reaction was used to examine NORAD, microRNA (miR)-155-5p, and suppressor of cytokine signaling 1 (SOCS1) mRNA expression levels. Western blotting was used to analyze SOCS1 protein expression. The malignancy of BC cells was assessed using the cell counting kit-8 (CCK-8), BrdU, and Transwell assays. Bioinformatics analysis, RNA immunoprecipitation assay, and dual-luciferase reporter gene assays were used to verify the targeted relationship between NORAD and miR-155-5p. Additionally, the regulatory effects of NORAD and miR-155-5p on SOCS1 expression were determined by western blotting. Results: NORAD expression was significantly reduced in BC cell lines and tissues, and its low expression was associated with poor tumor tissue differentiation. NORAD overexpression repressed BC cell proliferation, migration, and invasion, whereas its knockdown produced the opposite effects. Additionally, miR-155-5p was found to be a target of NORAD, and the biological functions of miR-155-5p and NORAD were counteractive. MiR-155-5p was confirmed to target SOCS1, and SOCS1 was found to be positively regulated by NORAD. Conclusion: NORAD suppresses miR-155-5p to upregulate SOCS1, thereby repressing the proliferation, migration, and invasion of BC cells.
-
Ting-Yan Shi,Sheng Yin,Jianqing Zhu,Ping Zhang,Jihong Liu,Libing Xiang,Yaping Zhu,Sufang Wu,Xiaojun Chen,Xipeng Wang,Yin-Cheng Teng,Tao Zhu,Aijun Yu,Yingli Zhang,Yanling Feng,He Huang,Wei Bao,Yanli Li 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.3
Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Moreover, poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance now has been a standard care for platinum sensitive relapsed OC. To our knowledge, no published or ongoing trial is trying to answer the question if patient can benefit from a potentially complete resection combined with PARPi maintenance in OC patients with secondary recurrence. Methods: SOC-3 is a multi-center, open, randomized, controlled, phase II trial of SCR followed by chemotherapy and niraparib maintenance vs chemotherapy and niraparib maintenance in patients with platinum-sensitive second relapsed OC who never received SCR at recurrence. To guarantee surgical quality, if the sites had no experience of participating in any OC-related surgical trials, the number of recurrent lesions evaluated by central-reviewed positron emission tomography–computed tomography image shouldn't be more than 3. Eligible patients are randomly assigned in a 1:1 ratio to receive either SCR followed by 6 cycles of platinum-based chemotherapy and niraparib maintenance or 6 cycles of platinum-based chemotherapy and niraparib maintenance alone. Patients who undergo at least 4 cycles of chemotherapy and must be, in the opinion of the investigator, without disease progression, will be assigned niraparib maintenance. Major inclusion criteria are secondary relapsed OC with a platinum-free interval of no less than 6 months and a possibly complete resection. Major exclusion criteria are borderline tumors and non-epithelial ovarian malignancies, received debulking surgery at recurrence and impossible to complete resection. The sample size is 96 patients. Primary endpoint is 12-month non-progression rate. Trial Registration: ClinicalTrials.gov Identifier: NCT03983226
-
Rong Jiang,Jianqing Zhu,김재원,Jihong Liu,Kazuyoshi Kato,김희승,Yuqin Zhang,Ping Zhang,Tao Zhu,Daisuke Aoki,Aijun Yu,Xiaojun Chen,Xipeng Wang,Ding Zhu,Wei Zhang,Huixun Jia,Ting-Yan Shi,Wen Gao,Sheng Yin,Yan 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.5
Background: Two randomized phase III trials (EORTC55971 and CHORUS) showed similarprogression-free and overall survival in primary or interval debulking surgery in ovariancancer, however both studies had limitations with lower rate of complete resection and lack ofsurgical qualifications for participating centers. There is no consensus on whether neoadjuvantchemotherapy followed by interval debulking surgery (NACT-IDS) could be a preferred approachin the management of advanced epithelial ovarian cancer (EOC) in the clinical practice. Methods: The Asian SUNNY study is an open-label, multicenter, randomized controlled,phase III trial to compare the effect of primary debulking surgery (PDS) to NACT-IDS instages IIIC and IV EOC, fallopian tube cancer (FTC) or primary peritoneal carcinoma (PPC). The hypothesis is that PDS enhances the survivorship when compared with NACT-IDS inadvanced ovarian cancer. The primary objective is to clarify the role of PDS and NACT-IDS inthe treatment of advanced ovarian cancer. Surgical quality assures include at least 50% of nogross residual (NGR) in PDS group in all centers and participating centers should be nationalcancer centers or designed ovarian cancer section or those with the experience participatingsurgical trials of ovarian cancer. Any participating center should be monitored evaluatingthe proportions of NGR by a training set. The aim of the surgery in both arms is maximalcytoreduction. Tumor burden of the disease is evaluated by diagnostic laparoscopy orpositron emission tomography/computed tomography scan. Patients assigned to PDS groupwill undergo upfront maximal cytoreductive surgery within 3 weeks after biopsy, followed by6 cycles of standard adjuvant chemotherapy. Patients assigned to NACT group will undergo 3cycles of NACT-IDS, and subsequently 3 cycles of adjuvant chemotherapy. The maximal timeinterval between IDS and the initiation of adjuvant chemotherapy is 8 weeks. Major inclusioncriteria are pathologic confirmed stage IIIC and IV EOC, FTC or PPC; ECOG performancestatus of 0 to 2; ASA score of 1 to 2. Major exclusion criteria are non-epithelial tumors as wellas borderline tumors; low-grade carcinoma; mucinous ovarian cancer. The sample size is 456subjects. Primary endpoint is overall survival. Trial Registration: ClinicalTrials.gov Identifier: NCT02859038
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
